Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

22.95
+0.61002.73%
Post-market: 23.040.0944+0.41%19:42 EDT
Volume:4.08M
Turnover:94.14M
Market Cap:2.88B
PE:-12.78
High:23.57
Open:22.26
Low:22.04
Close:22.34
Loading ...
Jan 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 22, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities